Associate Professor, Executive Director
Department of Biomedicine / Lars Bolund Institute of Regenerative Medicine
Aarhus University / BGI-Qingdao
Group leader of the laboratory for genome editing and regenerative medicine, Department of Biomedicine, Aarhus University
Dr. Luo received his PhD in Medicine from the Department of Biomedicine, Aarhus University. His PhD study has lead to the generation of first genetically modified BRCA1 KO pig model of breast cancer (Luo 2011 et al. Transgenic Res 20(5): 975-988; Luo 2012 et al. Transgenic Res 21(3): 671-676.). Meanwhile, his work has lead the optimization of several technologies used for targeted genetic modification of primary pig fibroblasts, as well as the generation of genetically modified porcine models of human disease.
After received his PhD, Dr. Luo received a two-year PostDoc fellowship from the Novo Nordisk R&D Science, Talent, Attraction and Recruitment (STAR) programme. His postdoctoral project is to establish the groundbreaking precision genome editing technology (TALENs) for generation of humanize porcine and rat models of diabetes. This still ongoing project has lead to the generation of a humanized pig models for diabetes research. More information regarding this porcine model of diabetes can be requested through Pixiegene A/S.
Since 2014, supported by the Danish Council for Independent Research, the Lundbeck Foundation, and the Department of Biomedicine, Aarhus University, Dr. Luo established his own research group with a focus on functional genomics and epigenomics research and regenerative medicine at the Department of Biomedicine, Aarhus University. The research group has a special focus on:
1. Establishing and generating precision genome and epigenome editing tools through modifying the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) system.
2. Development of disease-specific and genetically modified induced pluripotent stem cells for studying the pathogenesis of disease and stem cell-base cell therapy.
3. Generation of genetically modified porcine models of human diseases. These porcine models e.g. diabetes are used for studying the pathogenesis of human diseases as well as a model for preclinical testing of therapeutic interventions.